SEC For		_				~ ~-					<u></u>			001011				
FORM 4 UNITED ST					ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* NAGEL MICHAEL					- 3. [<mark>irom</mark> Date o	f Earliest	<u>pha</u>	ker or Tradin r <u>ma, Inc.</u> saction (Mon	[KI	RBP]	(Ch	5. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)			vner		
(Last) (First) (Middle) C/O KIROMIC BIOPHARMA INC. 7707 FANNIN, SUITE 140 (Street)						/05/2		Date o	of Original Fi	led (M	Ionth/Da	Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
HOUST((City)	- Ri	Person Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
		Tab	le I - Nor	n-Deri	vativ	e Se	curities	s Ac	quired, D	ispo	osed o	f, or Be	neficial	ly Owned	l			
1. Title of Security (Instr. 3) 2. Trans Date (Month)					ear) I	2A. Deemed Execution Date, f any Month/Day/Year)		Transaction Dis Code (Instr. 5)		Disposed	curities Acquired (A) osed Of (D) (Instr. 3, 4		Beneficia Owned F Reported	s Form ally (D) o ollowing (I) (Ir I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	/ A	Amount	(A) 01 (D)	Price	Transact (Instr. 3 a	ion(s) and 4)			
		٦							uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	Code (In				6. Date Exercisabl Expiration Date (Month/Day/Year)		le and	7. Title an of Securit Underlyin Derivative (Instr. 3 an	g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration e	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	10/05/2023			Α		18,000		10/05/2023		(1)	Common Stock	18,000	\$0	18,00	0	D	

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU.

/s/ Michael Nagel

10/06/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.